Survival prediction in essential thrombocythaemia (ET) and polycythaemia vera (PV) is currently based on clinically-derived variables; we examined the possibility of integrating genetic information for predicting survival. To this end, 906 molecularly-annotated patients (416 Mayo Clinic; 490 University of Florence, Italy), including 502 ET and 404 PV, were recruited. Multivariable analysis identified spliceosome mutations to adversely affect overall (SF3B1, SRSF2 in ET and SRSF2 in PV) and myelofibrosis-free (U2AF1, SF3B1 in ET) survival; TP53 mutations predicted leukaemic transformation in ET; “adverse” mutations occurred in 51 (10%) ET and 8 (2%) PV patients. We confirmed the independent survival effect of adverse mutations [hazard ratio (HR) 2·4, 95% CI 1·6–3·5], age >60 years (6·6, 4·6–9·7), male sex (1·8, 1·3–2·4) and leukocytosis ≥11 × 109/l (1·6, 1·1–2·2), in ET, and adverse mutations (7·8, 3·1–17·0), age >67 years (5·4, 3·6–8·1), leukocytosis ≥15 × 109/l (2·8, 1·8–4·2) and thrombosis history (2·0, 1·4–2·9), in PV. HR-based risk point allocation allowed development of three-tiered mutation-enhanced international prognostic systems (MIPSS) which were validated in both cohorts and performance was shown to be superior to conventional scoring systems. Spliceosome mutations enhance survival prediction in ET and PV and identify patients at risk for fibrotic progression. TP53 mutations predict leukaemic transformation in ET.

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera / Tefferi A.; Guglielmelli P.; Lasho T.L.; Coltro G.; Finke C.M.; Loscocco G.G.; Sordi B.; Szuber N.; Rotunno G.; Pacilli A.; Hanson C.A.; Ketterling R.P.; Pardanani A.; Gangat N.; Vannucchi A.M.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - ELETTRONICO. - 189:(2020), pp. 291-302. [10.1111/bjh.16380]

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera

Guglielmelli P.
Writing – Original Draft Preparation
;
Coltro G.
Writing – Review & Editing
;
Loscocco G. G.
Writing – Review & Editing
;
Sordi B.
Writing – Review & Editing
;
Rotunno G.
Writing – Review & Editing
;
Pacilli A.
Writing – Review & Editing
;
Vannucchi A. M.
Writing – Original Draft Preparation
2020

Abstract

Survival prediction in essential thrombocythaemia (ET) and polycythaemia vera (PV) is currently based on clinically-derived variables; we examined the possibility of integrating genetic information for predicting survival. To this end, 906 molecularly-annotated patients (416 Mayo Clinic; 490 University of Florence, Italy), including 502 ET and 404 PV, were recruited. Multivariable analysis identified spliceosome mutations to adversely affect overall (SF3B1, SRSF2 in ET and SRSF2 in PV) and myelofibrosis-free (U2AF1, SF3B1 in ET) survival; TP53 mutations predicted leukaemic transformation in ET; “adverse” mutations occurred in 51 (10%) ET and 8 (2%) PV patients. We confirmed the independent survival effect of adverse mutations [hazard ratio (HR) 2·4, 95% CI 1·6–3·5], age >60 years (6·6, 4·6–9·7), male sex (1·8, 1·3–2·4) and leukocytosis ≥11 × 109/l (1·6, 1·1–2·2), in ET, and adverse mutations (7·8, 3·1–17·0), age >67 years (5·4, 3·6–8·1), leukocytosis ≥15 × 109/l (2·8, 1·8–4·2) and thrombosis history (2·0, 1·4–2·9), in PV. HR-based risk point allocation allowed development of three-tiered mutation-enhanced international prognostic systems (MIPSS) which were validated in both cohorts and performance was shown to be superior to conventional scoring systems. Spliceosome mutations enhance survival prediction in ET and PV and identify patients at risk for fibrotic progression. TP53 mutations predict leukaemic transformation in ET.
2020
189
291
302
Tefferi A.; Guglielmelli P.; Lasho T.L.; Coltro G.; Finke C.M.; Loscocco G.G.; Sordi B.; Szuber N.; Rotunno G.; Pacilli A.; Hanson C.A.; Ketterling R....espandi
File in questo prodotto:
File Dimensione Formato  
Br J Haematol - 2020 - Tefferi - Mutation‐enhanced international prognostic systems for essential thrombocythaemia and (1).pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 551.28 kB
Formato Adobe PDF
551.28 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1260807
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 146
  • ???jsp.display-item.citation.isi??? 140
social impact